Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 20Neoplasm Metastasis 8Leukemia, Myeloid, Acute 7Skin Neoplasms 6Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Leukemia, Lymphocytic, Chronic, B-Cell 5Uveal Melanoma 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Rectal Neoplasms 3Pancreatic Neoplasms 3Mesothelioma, Malignant 3Lymphoma, Follicular 3Lymphoma 3Lung Neoplasms 3Leukemia 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Sarcoma 2Pleural Effusion, Malignant 2Neuroblastoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2

Interventions

Cyclophosphamide 8fludarabine 5Radiation 3Doxorubicin 3tazemetostat 2pembrolizumab 2Specimen Handling 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Leukapheresis 2Injections 2Ifosfamide 2peposertib 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1fludarabine phosphate 1anlotinib 1aldesleukin 1Zoledronic Acid 1X-Rays 1Trabectedin 1Tablets 1Rosuvastatin Calcium 1Quality of Life 1Phantoms, Imaging 1Nivolumab 1Midazolam 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × Interleukin-2 × 1 year × Clear all
NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Hadassah Medical Organization

Phase 1/2 Recruiting
3 enrolled
BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡